Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Conference Sponsor
2018 - 08 - 03
Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 3600 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China, owning to our involvement of  over 150 innovative drugs.Contact: www.tigermed.net  Email: bd@tigermed.net
2018 - 08 - 08
Founded in 1993, Fangda Partners has offices in major business districts in China, including Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong. With more than 500 practitioners, we serve both PRC and international clients successfully in various industries and are continuously involved in, advising on, and creating innovative legal structures for transactions in a whole spectrum of commercial areas such as capital markets, mergers and acquisitions, private equity, banking, structured finance, project finance, general corporate, inward investment, commercial property, tax, intellectual property, insolvency, telecommunications, media and Internet. Fangda is dedicated to meeting the specific needs of each client. In the wide range of fields in which we are involved, we place great emphasis on excellence of services, a commercial attitude to transactions, efficiency of costs and, of course, speed of response.
2018 - 09 - 07
PPC group was founded in 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies. PPC group offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials, including innovative phase I pharmacokinetic, generic bioequivalence and biosimilar studies, to pharmaceuticals companies. In addition, PPC group has conducted over 400 innovative phase II-IV trials, covering all 24 therapeutic arenas.  We have been audited more than 30 times by numerous regulatory authorities, including FDA, PMDA, CFDA,ANSM, NPRA and etc.To fulfill harmonized bioequivalence standard for phase I clinical site, PPC group has set up a phase I center in Taipei McKay memorial Hospital in 2012; and co-found a phase I center with Xuzhou medical hospital in early 2017. Combining the strengths of Xuzhou Medical University, PPC has established strong early phase drug development especially in the bioavailability and bioequivalence research field over the past two decades. In 2018, PPC had set up 3 more dedicated Phase I Units in Xuzhou Central Hospital, Huangshi Central Hospital and Shanghai Pudong People’s Hospital.